The global myasthenia gravis treatment market size is anticipated to reach USD 2.03 billion by 2028 and exhibit a CAGR of 7.5% during the forecast period. Fortune Business InsightsTM has presented this information in its report titled, “Myasthenia Gravis Treatment, 2021-2028”. The market size stood at USD 1.15 billion in 2020 and is expected to reach USD 1.22 billion in 2021. Additionally, the rising geriatric population is expected to be a significant market growth driver. Myasthenia Gravis Treatment Industry Developments- March 2021 –  Efgartigimod for the treatment of generalized myasthenia gravis was approved by the FDA, according to Argenx. March 2021 – Viela Bio, Inc. was bought by Horizon Therapeutics plc to bolster the company’s portfolio, pipeline, and therapeutic emphasis on rare illness medicines. Get Sample PDF Brochure: COVID-19 Impact- Considerable Decline in Hospital Tourism during the Pandemic to Hamper Market Growth The COVID-19 pandemic had a negative influence on the myasthenia gravis treatment market. Immunosuppressive drugs are commonly used, which weaken the immune system. As a result, these people are vulnerable to infections, such as COVID-19. As a result, during the pandemic in 2020, patient footfall at hospitals and clinics decreased significantly. Key manufacturers faced supply chain challenges and drug trial roadblocks. Furthermore, prominent companies expected considerable revenue from the novel medicines but saw a drop due to a disturbance in the treatment of myasthenia gravis patients. To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: About Us: Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in. Contact Us: Fortune Business Insights™ Pvt. Ltd. US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245Email:[email protected]